Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel

Brain Pathology

Volumn 27, Issue 2, 2017, Pages 146-159

  Zacher, Angela ^a   Kaulich, Kerstin ^a,b   Stepanow, Stefanie ^a   Wolter, Marietta ^a   Köhrer, Karl ^a   Felsberg, Jörg ^a   Malzkorn, Bastian ^a   Reifenberger, Guido ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

glioma; molecular diagnostics; mutation; next generation sequencing

Indexed keywords

AMPLICON; ARTICLE; ASTROCYTOMA; ATRX GENE; CHROMOSOME 1P; CHROMOSOME 9Q; CIC GENE; COPY NUMBER VARIATION; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; EGFR GENE; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IDH GENE; MOLECULAR DIAGNOSTICS; NEXT GENERATION SEQUENCING; OLIGODENDROGLIOMA; PROMOTER REGION; PTEN GENE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BIOPSY; TERT GENE; TUMOR CLASSIFICATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; ALPHA THALASSEMIA; BRAIN TUMOR; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR PATHOLOGY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; X LINKED MENTAL RETARDATION;

ISOCITRATE DEHYDROGENASE; TUMOR MARKER;

ALPHA-THALASSEMIA; ASTROCYTOMA; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GENES, P53; GENETIC TESTING; GLIOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ISOCITRATE DEHYDROGENASE; MENTAL RETARDATION, X-LINKED; MUTATION; PATHOLOGY, MOLECULAR; PROGNOSIS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84964354713     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12367     Document Type: Article

References (67)

1. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249.
2. Appin CL, Brat DJ (2015) Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. Adv Anat Pathol 22:50–58.
3. Bechet D, Gielen, Gerrit G H, Korshunov A, Pfister SM, Rousso C et al (2014) Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 128:733–741.
4. Brat DJ, Verhaak, Roel G W, Aldape KD, Yung WKA, Salama SR et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498.
5. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477.
6. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451–456.
7. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11–19.
8. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601.
9. Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J et al (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236–1242.
10. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL et al (2012) Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol 110:89–98.
11. Chun S, Fay JC (2009) Identification of deleterious mutations within three human genomes. Genome Res 19:1553–1561.
12. Cimino PJ, Bredemeyer A, Abel HJ, Duncavage EJ (2015) A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. Exp Mol Pathol 98:568–573.
13. Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N et al (2014) Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget 5: 8083–8092.
14. Do H, Dobrovic A (2012) Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil–DNA glycosylase. Oncotarget 3:546–558.
15. Do H, Dobrovic A (2015) Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem 61:64–71.
16. Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A et al (2015) Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 18:388–400.
17. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B et al (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14:121–130.
18. Felsberg J, Wolter M, Seul H, Friedensdorf B, Göppert M, Sabel MC, Reifenberger G (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501–507.
19. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA et al (2015) Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 21:555–559.
20. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X et al (2014) Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 20:1394–1396.
21. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125:913–916.
22. Jones DTW, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz H et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932.
23. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–203.
24. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr. et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026.
25. Koelsche C, Sahm F, Wöhrer A, Jeibmann A, Schittenhelm J, Kohlhof P et al (2014) BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Brain Pathol 24:221–229.
26. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081.
27. Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.
29. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of Tumours of the Central Nervous System. IARC: Lyon, pp. 13–68.
30. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International Society of Neuropathology—Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading. Brain Pathol 24:429–435.
31. Nikiforova MN, Wald AI, Melan MA, Roy S, Zhong S, Hamilton RL et al (2016) Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol 18: 379–387.
32. Pajtler KW, Witt H, Sill M, Jones DTW, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743.
33. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li Y et al (2014) C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506:451–455.
34. Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D et al (2015) Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol 17:1344–1355.
35. Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417.
36. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146.
37. Riemenschneider MJ, Jeuken JWM, Wesseling P, Reifenberger G (2010) Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 120:567–584.
38. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP (2011) Integrative genomics viewer. Nat Biotechnol 29:24–26.
39. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S et al (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551–559.
40. Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D et al (2015) Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol [Epub ahead of print] PMID:26671409.
41. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729.
42. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405.
43. Schmidt EE, Ichimura K, Reifenberger G, Collins VP (1994) CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54:6321–6324.
44. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD et al (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17:854–861.
45. Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J et al (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512:324–327.
46. Schwartzentruber J, Korshunov A, Liu X, Jones DTW, Pfaff E, Jacob K et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231.
47. Serizawa M, Yokota T, Hosokawa A, Kusafuka K, Sugiyama T, Tsubosa Y et al (2015) The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues. Cancer Genet 208:415–427.
48. Siepel A (2006) New methods for detecting lineage-specific selection. In: Research in Computational Molecular Biology, Vol. 3909. D Hutchison, T Kanade, J Kittler et al (eds), pp 190–205. Springer: Berlin.
49. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A et al (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231–1235.
50. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J et al (2014) Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer 111:2014–2023.
51. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B et al (2013) Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diag 15:607–622.
52. Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W et al (2009) Sample type bias in the analysis of cancer genomes. Cancer Res 69:5630–5633.
53. Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET et al (2015) Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg 122:1144–1150.
54. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y et al Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468.
55. Tabone T, Abuhusain HJ, Nowak AK; Australian Genomics and Clinical Outcome of Glioma (AGOG) Network, Erber WN, McDonald KL (2014) Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study. J Clin Pathol 67:550–555.
56. Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM et al (2014) A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol 128:743–753.
57. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164.
58. Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, Blaschke B et al (2007) Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. Oncogene 26:1088–1097.
59. Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T et al (2014) Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 134:2437–2447.
60. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A et al (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395–e403.
61. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693.
62. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM et al (2015) Glioma. Nat Rev Dis Primers 1, article number 15017: 1–18.
63. Wiestler B, Capper D, Sill M, Jones DTW, Hovestadt V, Sturm D et al (2014) Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128:561–571.
64. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251–253.
65. Yang CY, Liau JY, Huang WJ, Chang YT, Chang MC, Lee JC et al (2015) Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma. Am J Transl Res 7:2072–2081.
66. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612.
67. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD et al (2014) Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 20:1479–1484.